Stockscreener 앱 받기
72.51
0.12%
-0.09
전일 마감가:
$72.60
열려 있는:
$72.6
하루 거래량:
1.45M
Relative Volume:
0.32
시가총액:
$10.93B
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-20.39
EPS:
-3.5569
순현금흐름:
$-502.70M
1주 성능:
+0.19%
1개월 성능:
+0.75%
6개월 성능:
+116.25%
1년 성능:
+156.31%
1일 변동 폭
$72.47
$72.62
1주일 범위
$72.23
$72.70
52주 변동 폭
$21.51
$72.70
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
3020 CALLAN ROAD, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.51 | 10.94B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Aug Levels: Can Avidity Biosciences Inc continue delivering strong returnsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
Aug PostEarnings: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.63 USD - Investing.com India
Novartis (NYSE: NVS) details Avidity deal and Atrium SpinCo plans - Stock Titan
Understanding the Setup: (RNA) and Scalable Risk - Stock Traders Daily
Hedge Fund Moves: Can Avidity Biosciences Inc. stock sustain free cash flow growthMarket Trend Review & Real-Time Buy Signal Alerts - moha.gov.vn
Earnings Beat: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Avidity Biosciences, Inc. (RNA) Stock Analysis: Impressive Revenue Growth Amidst Biotech Sector Challenges - DirectorsTalk Interviews
Insider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 8,576 Shares of Stock - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Insider Sells 2,374 Shares of Stock - MarketBeat
Charles Calderaro III Sells 3,727 Shares of Avidity Biosciences (NASDAQ:RNA) Stock - MarketBeat
Novartis to acquire Avidity Biosciences for about $12B - MSN
Why Avidity Biosciences Inc. stock attracts high net worth investors2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Avidity Biosciences Inc. stock gain from strong economyOil Prices & Free Verified High Yield Trade Plans - ulpravda.ru
Avidity Biosciences (NASDAQ:RNA) Stock Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Strategic Clinical Trials - DirectorsTalk Interviews
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
The Technical Signals Behind (RNA) That Institutions Follow - Stock Traders Daily
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Is Avidity Biosciences Inc a good long term investmentStock Price Divergence & Market Monitoring and Alerts - earlytimes.in
Avidity Biosciences Earnings Notes - Trefis
Is Avidity Biosciences Inc. stock resilient to inflationSupport Zone Identification & High Return Trading Ideas - bollywoodhelpline.com
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Potential 3.47% Upside - DirectorsTalk Interviews
CEO Moves: Is Avidity Biosciences Inc stock a buy on dipsSwing Trade & Weekly High Return Opportunities - moha.gov.vn
Novartis to acquire Avidity Biosciences for about $12 billion - MSN
Assenagon Asset Management S.A. Has $2 Million Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock valuations compare to rivalsQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Exit Recap: Is Avidity Biosciences Inc. stock resilient to inflationJuly 2025 Spike Watch & Long-Term Growth Plans - ulpravda.ru
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 72.23 USD - Investing.com
Officer Calderaro III Surrenders 9,726 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Flanagan Surrenders 13,695 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Mosbrooker Surrenders 47,990 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Gallagher Surrenders 41,366 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer McCarthy Acquires 21,702 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI - MarketBeat
RNA SEC FilingsAvidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Novartis-Avidity Biosciences deal gets early clearance in US - MLex
Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65 - marketscreener.com
Avidity Biosciences Receives FTC Clearance for Novartis Merger - TipRanks
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Mirador Capital Partners LP Purchases 22,666 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
| Hughes Steven George | Chief Medical Officer |
Jan 07 '26 |
Sale |
72.23 |
2,373 |
171,402 |
36,494 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 07 '26 |
Sale |
72.23 |
2,373 |
171,402 |
91,627 |
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Option Exercise |
10.16 |
2,209 |
22,443 |
41,076 |
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
4.73%
0.92%
자본화:
|
볼륨(24시간):